Background and overview[1]
1-(3,5-Dichlorophenyl)piperazine can be used as a pharmaceutical synthesis intermediate. If 1-(3,5-dichlorophenyl)piperazine is inhaled, move the patient to fresh air; if skin contact occurs, remove contaminated clothing and rinse skin thoroughly with soap and water. If discomfort occurs , seek medical attention; if eye contact occurs, separate eyelids, rinse with running water or saline, and seek medical attention immediately; if ingested, rinse mouth immediately, do not induce vomiting, and seek medical attention immediately.
Preparation[1]
1-(3,5-Dichlorophenyl)piperazine can be used as a pharmaceutical synthesis intermediate, such as the preparation of compound 2-(((4-(3,5-dichlorophenyl)piperazine-1- (Bromoacetyl)amino)-6-methoxybenzothiazole, the specific steps are as follows: 2-((bromoacetyl)amino)-6-methoxybenzothiazole (1.0g, 3.32mmol), 1- (3,5-Dichlorophenyl)piperazine (1.0g, 4.40mmol) and anhydrous K2CO3 (0.61g, 4.40mmol) were dissolved in DMF (30mL), and the mixture was poured into ice water (200mL) and washed with EtOAc (3×50mL) extraction. The organic layer was dried (MgSO4), filtered, and the residue was purified by silica gel chromatography, eluting with hexane-ethyl acetate (2:1) to obtain 1.01 g (67%) of the title compound 2-(((4-(3) , 5-dichlorophenyl)piperazin-1-yl)acetyl)amino)-6-methoxybenzothiazole, solid, melting point 80-81°C:
1HNMR (DMSO-dg) δ12.03 (bs, 1H), 7.63 (d, J=9.2, 1H), 7.57 (d, J=2.4, 1H), 7.03 (dd, J=8.8, J= 2.4, 1H), 6.94 (d, J=1.6, 2H), 6.85 (t, J=1.6, 1H), 3.81 (s, 3H), 3.39 (s, 2H), 3.27 (t, J=4.8, 4H ), 2.65 (t, J=4.8, 4H);
13CNMR (DMSO-d6) δ168.97, 156.15, 155.43, 152.59, 142.52, 134.61, 132.74, 121.12, 116.93, 114.92, 113.02 (2C), 104.72, 59.91, 55.59, 52.05 (2C) ,47.14.
Main reference materials
[1] WO1999031096 PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS
